Related Experiment Video
Updated: Jul 10, 2026
08:27
Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
Published on: May 21, 2018
Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction
Shigeatsu Endo1, Nobuhiro Sato, Yasunori Yaegashi
1Department of Critical Care Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan. sendo@iwate-med.ac.jp
Research Communications in Molecular Pathology and Pharmacology
|November 3, 2007
Summary
Sivelestat sodium hydrate, a neutrophil elastase inhibitor, improved respiratory function and reduced inflammation in patients with septic acute lung injury. Early administration of sivelestat may be beneficial for treating this critical condition.
Area of Science:
- Critical care medicine
- Pharmacology
- Respiratory medicine
Background:
- Sepsis-induced acute lung injury (ALI) is a severe condition characterized by inflammation and impaired gas exchange.
- Polymorphonuclear leukocyte elastase (PMN-E) plays a key role in the pathogenesis of ALI.
- Effective therapeutic strategies for ALI remain limited.
Purpose of the Study:
- To evaluate the efficacy of sivelestat sodium hydrate, a selective PMN-E inhibitor, in patients with septic ALI.
- To assess the impact of sivelestat on respiratory function and inflammatory markers.
Main Methods:
- A clinical study involving patients with septic acute lung injury.
- Administration of sivelestat sodium hydrate to the treatment group.
- Monitoring of primary endpoints: duration of artificial ventilation and pulmonary oxygenation.
- Measurement of secondary endpoints: mortality, and blood concentrations of PMN-E, SP-D, TNF-alpha, and IL-8.
Main Results:
- Sivelestat treatment significantly reduced the duration of artificial ventilation.
- Pulmonary oxygenation ability improved in the sivelestat group.
- Blood concentrations of PMN-E, SP-D, TNF-alpha, and IL-8 were significantly decreased.
- Sivelestat administration reduced alveolar dysfunction and improved respiratory function.
Conclusions:
- Sivelestat sodium hydrate demonstrates potential as a therapeutic agent for septic acute lung injury.
- Early administration of sivelestat may improve outcomes by mitigating inflammation and enhancing respiratory function.
- Further research is warranted to confirm these findings and optimize treatment protocols.
Related Concept Videos
01:29Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:23Acute Respiratory Failure-IV
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
01:30Acute Respiratory Failure-III
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
01:21Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:21Acute Respiratory Failure-I
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
01:18Pulmonary Edema II: Pathophysiology
Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...